Active Ingredient History
Docetaxel was protected by patents (U.S. patent and European patent) which were owned by Sanofi-Aventis, and so was available only under the Taxotere brand name internationally. The European patent expired in 2010. Docetaxel is a clinically well-established anti-mitotic chemotherapy medication used for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Also used as a single agent in the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. It is also used in combination with prednisone, in the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. Furthermore, docetaxel has uses in the treatment of gastric adenocarcinoma and head and neck cancer. Docetaxel interferes with the normal function of microtubule growth. Whereas drugs like colchicine cause the depolymerization of microtubules in vivo, docetaxel arrests their function by having the opposite effect; it hyper-stabilizes their structure. This destroys the cell's ability to use its cytoskeleton in a flexible manner. Specifically, docetaxel binds to the β-subunit of tubulin. Tubulin is the "building block" of mictotubules, and the binding of docetaxel locks these building blocks in place. The resulting microtubule/docetaxel complex does not have the ability to disassemble. This adversely affects cell function because the shortening and lengthening of microtubules (termed dynamic instability) is necessary for their function as a transportation highway for the cell. Chromosomes, for example, rely upon this property of microtubules during mitosis. Further research has indicated that docetaxel induces programmed cell death (apoptosis) in cancer cells by binding to an apoptosis stopping protein called Bcl-2 (B-cell leukemia 2) and thus arresting its function. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Breast Neoplasms (approved 1996)
Carcinoma, Non-Small-Cell Lung (approved 1996)
Head and Neck Neoplasms (approved 1996)
Prostatic Neoplasms, Castration-Resistant (approved 1996)
Stomach Neoplasms (approved 1996)
Acute Kidney Injury (Phase 2)
Adenocarcinoma (Phase 3)
Adenocarcinoma, Clear Cell (Phase 3)
Adenocarcinoma, Mucinous (Phase 3)
Adenocarcinoma of Lung (Phase 3)
Adrenocortical Carcinoma (Phase 2)
Anemia (Phase 2)
Angiogenesis Modulating Agents (Phase 2)
Anorexia (Phase 3)
Anthracyclines (Phase 2)
Anus Neoplasms (Phase 2)
Ascites (Phase 2)
Astrocytoma (Phase 1)
Biliary Tract Neoplasms (Phase 2)
Brain Neoplasms (Phase 2)
BRCA1 Protein (Phase 2)
Breast Carcinoma In Situ (Phase 2)
Breast Diseases (Phase 3)
Breast Neoplasms, Male (Phase 1/Phase 2)
Brenner Tumor (Phase 3)
Bronchial Neoplasms (Phase 3)
Cachexia (Phase 3)
Carboplatin (Phase 3)
Carcinoma (Phase 3)
Carcinoma, Bronchogenic (Phase 3)
Carcinoma, Ductal (Phase 2)
Carcinoma, Ductal, Breast (Phase 3)
Carcinoma, Hepatocellular (Phase 2)
Carcinoma, Large Cell (Phase 2)
Carcinoma, Neuroendocrine (Phase 2)
Carcinoma, Ovarian Epithelial (Phase 3)
Carcinoma, Renal Cell (Phase 2)
Carcinoma, Squamous Cell (Phase 4)
Carcinoma, Transitional Cell (Phase 3)
Carcinoma, Verrucous (Phase 3)
Cardiotoxicity (Phase 3)
Castration (Phase 3)
Chemical and Drug Induced Liver Injury (Phase 4)
Chemoradiotherapy (Phase 3)
Cholangiocarcinoma (Phase 2)
Circulating Tumor DNA (Phase 2)
Cisplatin (Phase 3)
Colitis, Ulcerative (Phase 2)
Colonic Neoplasms (Phase 2/Phase 3)
Colorectal Neoplasms (Phase 2)
Congenital Hyperinsulinism (Phase 2)
Cytoreduction Surgical Procedures (Phase 2)
Disease-Free Survival (Phase 2/Phase 3)
Disseminated Intravascular Coagulation (Phase 2)
Docetaxel (Phase 2/Phase 3)
Drugs, Investigational (Phase 3)
Drug Therapy (Phase 3)
Endometrial Neoplasms (Phase 3)
Enteral Nutrition (Phase 3)
ErbB Receptors (Phase 2)
Esophageal Diseases (Phase 3)
Esophageal Neoplasms (Phase 3)
Esophageal Squamous Cell Carcinoma (Phase 3)
Esophagogastric Junction (Phase 3)
Fallopian Tube Neoplasms (Phase 3)
Fatigue (Phase 3)
Febrile Neutropenia (Phase 2)
Fever (Phase 2)
Fibrosarcoma (Phase 2)
Fluorouracil (Phase 2/Phase 3)
Gallbladder Neoplasms (Phase 2)
Gastrointestinal Diseases (Phase 1/Phase 2)
Gastrointestinal Neoplasms (Phase 3)
Genes, erbB-1 (Phase 2)
Genes, erbB-2 (Phase 1)
Genetic Predisposition to Disease (Phase 3)
Glaucoma (Phase 1)
Glioblastoma (Phase 1)
Glioma (Phase 1)
Graft vs Host Disease (Phase 2)
Hamartoma (Phase 3)
Head and Neck Neoplasms (Phase 4)
Hemangiosarcoma (Phase 2)
Histiocytoma (Phase 2)
Homologous Recombination (Phase 2)
Hormones (Phase 2)
Hypopharyngeal Neoplasms (Phase 3)
Immunotherapy (Phase 2)
Inflammatory Breast Neoplasms (Phase 3)
Intestinal Neoplasms (Phase 2)
Irinotecan (Phase 2/Phase 3)
Kidney Neoplasms (Phase 3)
Lapatinib (Phase 2)
Laryngeal Neoplasms (Phase 3)
Larynx (Phase 2)
Leiomyosarcoma (Phase 3)
Leukemia (Phase 2)
Leukemia, Myeloid, Acute (Phase 3)
Liposarcoma (Phase 2)
Liver Diseases (Phase 1)
Liver Neoplasms (Phase 2)
Lung Diseases (Phase 3)
Lung Neoplasms (Phase 4)
Lymphoma (Phase 1/Phase 2)
Mediastinal Neoplasms (Phase 2)
Medical Oncology (Phase 1)
Melanoma (Phase 2)
Mouth Neoplasms (Phase 3)
Multiple Myeloma (Phase 2)
Mutation (Phase 3)
Myelodysplastic Syndromes (Phase 1/Phase 2)
Myeloproliferative Disorders (Phase 2)
Nasal Cavity (Phase 2)
Nasopharyngeal Carcinoma (Phase 3)
Nasopharyngeal Neoplasms (Phase 2)
Nausea (Phase 3)
Neoadjuvant Therapy (Phase 3)
Neoplasm Metastasis (Phase 3)
Neoplasm Recurrence, Local (Phase 2/Phase 3)
Neoplasms ()
Neoplasms by Site (Phase 3)
Neoplasms, Second Primary (Phase 4)
Neoplasms, Squamous Cell (Phase 2)
Neoplastic Cells, Circulating (Phase 2)
Neuregulin-1 (Phase 2)
Neuroblastoma (Phase 2)
Neurofibrosarcoma (Phase 1/Phase 2)
Neutropenia (Phase 3)
Ocular Hypertension (Phase 1)
Oropharyngeal Neoplasms (Phase 3)
Osteosarcoma (Phase 3)
Ovarian Diseases (Phase 3)
Ovarian Neoplasms (Phase 3)
Oxaliplatin (Phase 2/Phase 3)
Pain (Phase 3)
Pancreatic Neoplasms (Phase 3)
Papillomaviridae (Phase 2)
Papillomavirus Infections (Phase 2)
Paranasal Sinuses (Phase 2)
Paranasal Sinus Neoplasms (Phase 3)
Pathology (Phase 3)
Pemetrexed (Phase 2)
Penile Neoplasms (Phase 2)
Peritoneal Neoplasms (Phase 3)
Pharmaceutical Preparations (Phase 2)
Pharmacokinetics (Phase 1)
Pharyngeal Neoplasms (Phase 3)
Pleural Effusion, Malignant (Phase 2)
Postoperative Complications (Phase 3)
Precancerous Conditions (Phase 2)
Progression-Free Survival (Phase 2/Phase 3)
Prostatic Neoplasms (Phase 4)
Proto-Oncogene Proteins B-raf (Phase 2)
Radiation Oncology (Phase 2)
Rectal Neoplasms (Phase 2)
Respiratory Tract Diseases (Phase 3)
Respiratory Tract Neoplasms (Phase 3)
Rhabdomyosarcoma (Phase 2)
Safety (Phase 2)
Salivary Gland Neoplasms (Phase 3)
Sarcoma (Phase 3)
Sarcoma, Ewing (Phase 2)
Sarcoma, Synovial (Phase 2)
Sepsis (Phase 2)
Skin Diseases (Phase 3)
Small Cell Lung Carcinoma (Phase 3)
Squamous Cell Carcinoma of Head and Neck (Phase 4)
Stomach Neoplasms (Phase 3)
Survival (Phase 3)
Testicular Neoplasms (Phase 2)
Therapeutic Equivalency (Phase 1)
Thoracic Neoplasms (Phase 3)
Thromboembolism (Phase 2)
Thymoma (Phase 2)
Thyroid Neoplasms (Phase 2)
Tongue Neoplasms (Phase 3)
Tonsillar Neoplasms (Phase 2)
Triple Negative Breast Neoplasms (Phase 3)
Ureteral Neoplasms (Phase 3)
Urethral Neoplasms (Phase 3)
Urinary Bladder Diseases (Phase 1/Phase 2)
Urinary Bladder Neoplasms (Phase 3)
Urogenital Neoplasms (Phase 1/Phase 2)
Urologic Diseases (Phase 1/Phase 2)
Urologic Neoplasms (Phase 1/Phase 2)
Uterine Cervical Neoplasms (Phase 3)
Uterine Neoplasms (Phase 2)
Vaginal Neoplasms (Phase 1)
Vulvar Neoplasms (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
